Maravai LifeSciences (MRVI) Investor presentation summary

Business overview and strategic positioning

• Provides critical solutions for mRNA, gene editing, cell and gene therapy, vaccines, and biologics from discovery to commercialization.

• TriLink offers proprietary mRNA technologies, specialty chemistry, and CDMO services supporting clinical development.

• Cygnus delivers assays and analytical services for impurity detection in biotherapeutic manufacturing, with broad adoption in CAR-T and gene therapies.

• Serves 96% of the top 25 global biopharma R&D spenders, including major industry leaders.

• Led by a new management team with significant turnaround and industry experience.

Financial performance and transformation

• Achieved stabilization post-organizational changes, exceeding $65M in cost reductions and returning to positive adjusted EBITDA in 1H 2026.

• 1H 2026 revenue reached $117.3M, up 24% YoY, with adjusted gross margin at 62.5% and adjusted EBITDA at $29.0M.

• TriLink base revenue grew 13% YoY, Cygnus base revenue up 2% YoY, and overall base revenue increased 9% YoY.

• Transitioned from COVID-dependent revenue to a streamlined growth platform, with cost alignment and innovation driving improved results.

• Focused on commercial execution, operational excellence, and R&D innovation for sustainable, profitable growth.

Strategic priorities and operational initiatives

• Deepening engagement with biopharma customers and expanding e-commerce and digital platforms.

• Centralized operations and increased automation to drive efficiency and scalability.

• Prioritizing high-return opportunities and expanding the GMP product portfolio.

• Robust pipeline of new products planned for 2026 to support continued growth.

• Structural improvements position the company for margin expansion and enhanced financial performance.